14 / 74 · 1:06 · Original AXON film
BPC-157 + TB-500
The burned-in captions and transcript carry the scientific claims and their limitations. The visuals are conceptual illustrations, not validated molecular models or experimental images. The video has no voice or audio. The full explanation is visible on screen; optional accessible captions are available in the player.
Read every result in its study context. A cell experiment, animal model, exploratory analysis and controlled human trial answer different questions.
Prepared 05 November 2026. Regulatory status is jurisdiction- and date-specific. No claim of specialist review or exhaustive evidence coverage.
Transcript
BPC-157 + TB-500
When two research compounds are paired, ask a simple question: did the study actually test both together? That matters for BPC-157 and TB-500. [1] [2]
Full-length peptide ≠ fragment
BPC-157 has tendon-cell and animal injury experiments. Many claims around TB-500 borrow from work on full-length thymosin beta-four, although the fragment is a different substance. [1] [3] [2]
Mechanism is not clinical validation
Possible roles in cell movement or repair do not demonstrate that the pair heals injuries faster in people. Combination effects and risks need direct testing. [1] [2]
Experimental combination
FDA’s technical reviews describe substantial evidence gaps. A careful explanation should end with what remains unknown, without offering a recovery protocol or a guaranteed result. [4] [2]
Sources and context
These linked sources support the evidence distinctions in this short overview. This is not a systematic review, endorsement or treatment recommendation.
- The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration →Primary rat tendon explant and tendon-cell study
- FDA Pharmacy Compounding Advisory Committee briefing: TB-500-related bulk drug substances →US regulator technical identity and evidence assessment; July 2026
- Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth →Primary rat injury and cell study
- FDA Pharmacy Compounding Advisory Committee briefing: BPC-157-related bulk drug substances →US regulator technical assessment; July 2026 advisory process, not marketing approval
